Navigation Links
Indiana Biosciences Research Institute Hits $50 Million Start-Up Funding Goal
Date:11/19/2013

INDIANAPOLIS, Nov. 19, 2013 /PRNewswire/ -- The Indiana Biosciences Research Institute announced today that it has reached the first $50 million funding milestone, fueling continued momentum in the development of the nation's first industry-led biosciences research institute.

Officially launched in a public announcement on May 30 by Indiana Governor Mike Pence with leading Hoosier companies and universities, the research institute serves as the catalyst to advancing the state's life sciences strengths. The Institute, which will attract world-class scientific leaders and research dollars to Indiana, will accelerate collaboration across and among Indiana's substantial academic and commercial research assets while focusing on human health solutions for improving the lives of Hoosiers and people around the world.

In less than 5 months, the Indiana Biosciences Research Institute has raised $25 million from corporate and philanthropic funders, matching the $25 million appropriated by the Indiana General Assembly earlier this year.

Eli Lilly and Company, whose Chairman and CEO, John Lechleiter, Ph.D., joined Governor Pence in 2012 in calling for the establishment of a biosciences research institute, has committed $7.5 million in start-up funding.

"Today's announcement represents a significant investment by Lilly in the future of Indiana and in the future of biosciences research," Lechleiter said. "Each year in Indiana, billions of dollars are invested in research and development to advance medical innovation. This Institute will help Indiana attract additional global talent and will nurture partnerships across the state and across the country - keeping more research dollars in Indiana and attracting more federal research funds to our state.

"In the last decade, Indiana has come of age as a recognized leader in the life sciences - with demonstrated capabilities in biopharmaceuticals, medical devices, and diagnostics, as well as in the areas of animal health and crop sciences. The research institute will fuel Indiana's economy and will underscore the state's position as a life sciences leader. The bio-landscape of Indiana is fertile ground for the Institute, and Lilly is proud to be a part of it."

An additional $4.5 million in start-up funding comes from Roche Diagnostics, with additional funding from Dow AgroSciences, Indiana University Health and Indiana University.

"The Indiana Biosciences Research Institute is one of the most dramatic demonstrations of how well our State leverages its strengths for widespread benefit," said Jack Phillips, president and CEO of Roche Diagnostics. "Not only have our State leadership and corporate partners committed financial resources to the Institute, but they have worked closely with our university partners and others to ensure we build an institute that is unlike any in the nation." 

The $50 million in funding better positions the Institute to recruit a world-class CEO, attract outstanding scientific talent, successfully initiate its scientific activities and organize the next phase of the capital campaign. The Indiana Biosciences Research Institute board of directors officially launched its CEO search in September and has made significant progress in collaboration with its university partners in defining its university engagement frameworks for intellectual property, Indiana Fellow university affiliations, and core laboratory access and use.  

"The development of the Indiana Biosciences Research Institute is rapidly progressing due to the overwhelming support and collaboration of the State of Indiana, and statewide corporate, philanthropic and academic partners," said David Johnson, president and CEO of BioCrossroads. "The Institute is a centerpiece project of BioCrossroads, an initiative that advances the state's life sciences strengths, and is an example on a grand level of how collaboration builds our life sciences leadership position."

The estimated $360-million Indiana Biosciences Research Institute is a non-profit entity. The $50 million in start-up funding will be followed by a campaign to raise an additional $310 million in corporate and philanthropic funding to support further Institute development and operating costs. Long-term, Institute operating costs will be funded through the development of the Institute's own endowment, industry-sponsored research and federally funded research.

As part of the Institute's development process, industry leaders have defined common scientific interests for research and discovery. The Institute will initially focus on the most pressing issues of human health: cardiovascular disease, diabetes, obesity and nutrition. These interrelated metabolic disorders are a major economic burden and a leading cause of death in the United States. Approximately 35 percent of Americans suffer from cardiovascular disease and metabolic disorders, including a disproportionate percentage of Hoosiers who suffer from these diseases.

About the Indiana Biosciences Research Institute 
The Indiana Biosciences Research Institute was incorporated in May 2013 and is the first industry-led biosciences research institute in the nation. The Institute is being developed by industry executives from Eli Lilly and Company, Dow AgroSciences, Roche Diagnostics, Cook Medical, Indiana University Health and Biomet, the Governor of Indiana, with active support in initial development by BioCrossroads. Indiana's research institutions, including Indiana University, Purdue University and the University of Notre Dame also are participating in the development process. More information about the Indiana Biosciences Research Institute can be found at www.indianabiosciences.org.


'/>"/>
SOURCE Indiana Biosciences Research Institute
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Indiana leads U.S. in life sciences jobs and growth
2. Indianas Stop-Sale System Achieves Significant Results In Battle Against Meth
3. Lilly to Expand Indianapolis Insulin Manufacturing Operations
4. CHPA Statement on Statewide Indiana Consumer Poll
5. Contract Manufacturer RMI hosts Central Indiana Jobs Roundtable with U.S. Senator Joe Donnelly
6. Lilly Statement on Indiana Biosciences Research Institute
7. Lilly to host investment community meeting at its Indianapolis headquarters on Thursday, October 3, 2013
8. 1,200th Worldwide Implant of the SynCardia Total Artificial Heart Occurs in Indiana
9. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
10. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
11. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... N.J. , Dec. 3, 2016  Findings ... and safety of CTL019, an investigational chimeric antigen ... (r/r) pediatric and young adult patients with B-cell ... during an oral session at the 58th American ... December 3, 4:00-5:30 p.m.). The global Phase II ...
(Date:12/2/2016)... bioLytical Laboratories, un líder mundial en test rápidos de ... Self Test , a los miembros de la Kenya Pharmaceutical Association. ... ... INSTI HIV Self Test! (PRNewsFoto/bioLytical Laboratories) ... (Photo: http://photos.prnewswire.com/prnh/20161201/444905 ) bioLytical fue invitada por la Clinton ...
(Date:12/2/2016)... According to the latest market report ... Automated Endoscope Reprocessors: Single Basin Automated Endoscope Reprocessors Product Type ... and 2024 " the global automated endoscope reprocessors market was valued at US$ ... a CAGR of 7.2% during an eight-year forecast period 2016-2024, ... 2024. ...
Breaking Medicine Technology:
(Date:12/4/2016)... ... December 03, 2016 , ... The Lymphoma Research Foundation (LRF) ... and serving the lymphoma community through a comprehensive series of education programs, outreach ... in New York City, with long-time partners The Paul Foundation, on November 10, ...
(Date:12/4/2016)... ... 04, 2016 , ... "Pro3rd Displace is a set of ... displacement design elements," said Christina Austin - CEO of Pixel Film Studios. ... of design styles that include both left aligned and right aligned options for ...
(Date:12/2/2016)... ... ... Lori G. Cohen and Sara K. Thompson , shareholders in global ... Institute’s 21st Drug & Medical Device Litigation Conference , taking place in New York ... who chairs the firm’s Pharmaceutical, Medical Device & Health Care Litigation Practice and the ...
(Date:12/2/2016)... ... 02, 2016 , ... Advanced Inc., a leading provider of travel therapy and ... to serve as Advanced Inc.’s Chief Financial Officer, effective December 1, 2016. Jason previously ... financial and operational leadership experience to Advanced Inc. He began his career in finance ...
(Date:12/2/2016)... ... December 02, 2016 , ... With the number of pain management programs ... patients must find the one that works for them. When an inventor from Suisun ... that worked and decided to share it with others. , He developed a prototype ...
Breaking Medicine News(10 mins):